articleJournal of Medicinal ChemistryApr 6, 2020HYBRID OA

Identification of the Clinical Development Candidate MRTX849 , a Covalent KRAS G12C Inhibitor for the Treatment of Cancer

JBJay B. FellJPJohn P. FischerBRBrian R. BaerJFJames F. BlakeKBKaryn Bouhana

Array BioPharma (United States) · Mirati Therapeutics (United States)

PubMed
Indexed incrossrefdatacitepubmed

Abstract

Is described.

Citation impact

589
total citations
FWCI
24.34
Percentile
100%
References
31
Citations per year

Authors

34

Topics & keywords

Topics
Keywords
  • Chemistry
  • Covalent bond
  • Cysteine
  • KRAS
  • Drug discovery
  • Drug development
  • Pharmacology
  • Potency
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.